A Benefit-Based Approach to Cholesterol-Lowering Prevention: A Proposal for Guideline-Friendly Individualization

This commentary proposes a “benefit-based” framework for cholesterol-lowering prevention decisions — arguing that treatment decisions should be based on absolute cardiovascular risk reduction (the benefit actually achieved) rather than risk threshold crossing or treatment intensity alone.

The framework centers on the observation that treatment benefit from lipid-lowering is proportional to both baseline absolute risk and the magnitude of atherogenic particle reduction achieved. A patient with high ApoB, high baseline risk, and a large absolute reduction in ApoB from treatment gains substantially more benefit than a patient at lower baseline risk achieving a similar percentage reduction. The commentary argues that guidelines anchored in risk strata and LDL-C thresholds miss this nuance.

Practically, the benefit-based approach would individualize treatment intensity based on estimated absolute event reduction rather than standardized strata — a direction that has since influenced the ACC/AHA “four statin benefit groups” concept and the growing emphasis on shared decision-making about treatment intensity.

As a commentary with only three references, this piece offers a conceptual framework rather than empirical evidence. Its importance lies in its influence on thinking about how to translate population-level trial evidence into individualized treatment decisions — a recognized gap in current guideline implementation.

We rate the evidence limited. A conceptual commentary proposing a benefit-based individualization framework for cholesterol-lowering prevention — thought-provoking advocacy for a more nuanced approach to prevention decisions, but without empirical data.